Panbela Therapeutics, Inc. financial data

Symbol
PBLA on Nasdaq
Industry
Pharmaceutical Preparations
Location
712 Vista Blvd #305, Waconia, Minnesota
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Sun BioPharma, Inc. (to 12/2/2020), Cimarron Medical, Inc. (to 9/4/2015), CIMARRON SOFTWARE INC (to 5/26/2015)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 41.5 % -11.3%
Debt-to-equity -1.04 K % -276%
Return On Equity 1.95 K % +150%
Return On Assets -208 % +53.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.85 M shares -66.7%
Common Stock, Shares, Outstanding 4.85 M shares -69.8%
Entity Public Float 6 M USD -47.5%
Common Stock, Value, Issued 5 K USD -68.8%
Weighted Average Number of Shares Outstanding, Basic 3.13 M shares +23912%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 22.6 M USD -22.9%
General and Administrative Expense 4.89 M USD -12.8%
Operating Income (Loss) -27.5 M USD +21.3%
Nonoperating Income (Expense) -81 K USD +94.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.6 M USD +24.3%
Income Tax Expense (Benefit) -324 K USD -272%
Net Income (Loss) Attributable to Parent -27.3 M USD +25%
Earnings Per Share, Basic -2.28 USD/shares +99.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 262 K USD -95%
Assets, Current 1.79 M USD -77.2%
Other Assets, Noncurrent 8.74 M USD +1.16%
Assets 10.5 M USD -36.1%
Accounts Payable, Current 8.51 M USD +15.9%
Accrued Liabilities, Current 979 K USD -28.2%
Liabilities, Current 10.5 M USD +7.93%
Liabilities 13.7 M USD -1.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.2 M USD +30.6%
Retained Earnings (Accumulated Deficit) -133 M USD -37.8%
Stockholders' Equity Attributable to Parent -3.19 M USD -226%
Liabilities and Equity 10.5 M USD -36.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.39 M USD +3.68%
Net Cash Provided by (Used in) Financing Activities 7.08 M USD -48.3%
Net Cash Provided by (Used in) Investing Activities 400 K USD
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 4.85 M shares -69.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.32 M USD -159%
Interest Paid, Excluding Capitalized Interest, Operating Activities 266 K USD -31.1%
Deferred Tax Assets, Valuation Allowance 26.3 M USD +20.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 26.3 M USD +20.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27 M USD +23.5%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 18.5 M USD +5.26%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -186 K USD -60.3%
Preferred Stock, Shares Authorized 10 M shares 0%
Additional Paid in Capital 128 M USD +31.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 103 K USD -42.8%
Interest Expense 278 K USD -28.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%